Phesgo and Tecentriq Performance and Approvals
2023: Key late-stage news flow*
Regulatory
Phase III / pivotal
readouts
Compound
Hemlibra
Polivy + R-CHP
Vabysmo
Tecentriq
Columvi (glofitamab)
Xofluza
Tecentriq + Avastin
Tecentriq + chemo
Tecentriq
Tecentriq + chemo
Tiragolumab + Tecentriq
Tiragolumab + Tecentriq + chemo
Venclexta + dexamethasone
Venclexta + azacitidine
Alecensa
Phesgo OBI (on body injector)
Crovalimab
Columvi + GemOx
Lunsumio + Polivy
Delandistrogene moxeparvovec (SRP-9001)
Ocrevus 6m SC
Indication
Moderate hemophilia A
1L DLBCL
RVO
Subcutaneous administration
3L+ DLBCL
Influenza (paediatric 1+ yrs.)
Adjuvant HCC
Neoadjuvant/adjuvant TNBC
Adjuvant SCCHN
Adjuvant TNBC
1L PDL 1+ NSCLC
1L esophageal cancer
t(11;14) R/R MM
1L high risk MDS
Adjuvant ALK+ NSCLC
HER2+ BC
PNH
2L+ DLBCL
2L+ DLBCL
DMD
Milestone
EU approval
US approval
US approval/EU filing
US approval/EU filing
US/EU approval
EU approval
Ph III IMbrave050
Ph III GeparDouze/NSABP B-59
Ph III IMvoke010
Ph III IMpassion030
Ph III SKYSCRAPER-01
Ph III SKYSCRAPER-08 (China only)
Ph III CANOVA
Ph III VERONA
Ph III ALINA
Ph I (pivotal)
Ph III COMMODORE 1/2
Ph III STARGLO
Ph III SUNMO**
Ph III EMBARK
Ph III OCARINA II
RMS/PPMS
Stroke patients 4.5-24h
Ph III TIMELESS
DME
Ph III PAGODA
TNKase
Susvimo
Susvimo
DR
Xolair
Food allergy
Outcome studies are event-driven: timelines may change; i
**
Results are event-driven; read-outs expected in 2023/24
Ph III PAVILION
Ph III OUTMATCH
Roche
EU filing
༨༨
32
32View entire presentation